ID   NOD2_BOVIN              Reviewed;        1013 AA.
AC   Q6E804;
DT   26-MAY-2009, integrated into UniProtKB/Swiss-Prot.
DT   16-AUG-2004, sequence version 1.
DT   04-MAR-2015, entry version 88.
DE   RecName: Full=Nucleotide-binding oligomerization domain-containing protein 2;
DE   AltName: Full=Caspase recruitment domain-containing protein 15;
GN   Name=NOD2; Synonyms=CARD15;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANTS ALA-70;
RP   MET-196; ASN-505; GLN-681; HIS-689; ARG-733 AND LEU-1007.
RX   PubMed=16897345; DOI=10.1007/s00335-005-0148-2;
RA   Taylor K.H., Taylor J.F., White S.N., Womack J.E.;
RT   "Identification of genetic variation and putative regulatory regions
RT   in bovine CARD15.";
RL   Mamm. Genome 17:892-901(2006).
CC   -!- FUNCTION: Recognizes muramyl dipeptide (MDP) constituents of
CC       bacterial peptidoglycans and plays a key role in gastrointestinal
CC       immunity: upon stimulation, binds the proximal adapter receptor-
CC       interacting RIPK2, which recruits ubiquitin ligases as XIAP,
CC       BIRC2, BIRC3 and the LUBAC complex, triggering activation of MAP
CC       kinases and activation of NF-kappa-B signaling, leading to
CC       activate the transcription of hundreds of genes involved in immune
CC       response. {ECO:0000250}.
CC   -!- SUBUNIT: Found in a signaling complex consisting of ARHGEF2, NOD2
CC       and RIPK2. Interacts (via CARD domain) with RIPK2 (via CARD
CC       domain). Interacts with ATG16L1. Interacts (via NACHT domain) with
CC       CARD9. Interacts with ANKRD17 (via N-terminus). Interacts with
CC       HSPA1A; the interaction enhances NOD2 stability. Interacts (via
CC       both CARD domains) with HSP90; the interaction enhances NOD2
CC       stability. Interacts (via CARD domain) with SOCS3; the interaction
CC       promotes NOD2 degradation. Interacts (via CARD domain) with
CC       ERBBI2P; the interaction inhibits activation of NOD2.
CC       {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9HC29}.
CC       Membrane {ECO:0000250|UniProtKB:Q9HC29}. Basolateral cell membrane
CC       {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- DOMAIN: The ATG16L1-binding motif mediates interaction with
CC       ATG16L1. {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated following MDP stimulation, leading to
CC       proteasome-madiated degradation. {ECO:0000250|UniProtKB:Q9HC29}.
CC   -!- SIMILARITY: Contains 2 CARD domains. {ECO:0000255|PROSITE-
CC       ProRule:PRU00046}.
CC   -!- SIMILARITY: Contains 9 LRR (leucine-rich) repeats. {ECO:0000305}.
CC   -!- SIMILARITY: Contains 1 NACHT domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00136}.
DR   EMBL; AY518737; AAS09824.1; -; mRNA.
DR   EMBL; AY518748; AAS09826.1; -; Genomic_DNA.
DR   EMBL; AY518739; AAS09826.1; JOINED; Genomic_DNA.
DR   EMBL; AY518740; AAS09826.1; JOINED; Genomic_DNA.
DR   EMBL; AY518741; AAS09826.1; JOINED; Genomic_DNA.
DR   EMBL; AY518742; AAS09826.1; JOINED; Genomic_DNA.
DR   EMBL; AY518743; AAS09826.1; JOINED; Genomic_DNA.
DR   EMBL; AY518744; AAS09826.1; JOINED; Genomic_DNA.
DR   EMBL; AY518745; AAS09826.1; JOINED; Genomic_DNA.
DR   EMBL; AY518746; AAS09826.1; JOINED; Genomic_DNA.
DR   EMBL; AY518747; AAS09826.1; JOINED; Genomic_DNA.
DR   RefSeq; NP_001002889.1; NM_001002889.1.
DR   RefSeq; XP_005218524.1; XM_005218467.2.
DR   RefSeq; XP_010812724.1; XM_010814422.1.
DR   RefSeq; XP_010812725.1; XM_010814423.1.
DR   UniGene; Bt.30778; -.
DR   ProteinModelPortal; Q6E804; -.
DR   STRING; 9913.ENSBTAP00000027887; -.
DR   Ensembl; ENSBTAT00000027887; ENSBTAP00000027887; ENSBTAG00000020936.
DR   GeneID; 444867; -.
DR   KEGG; bta:444867; -.
DR   CTD; 64127; -.
DR   eggNOG; NOG248107; -.
DR   GeneTree; ENSGT00780000121843; -.
DR   HOGENOM; HOG000113814; -.
DR   InParanoid; Q6E804; -.
DR   KO; K10165; -.
DR   OMA; NVGHLKL; -.
DR   OrthoDB; EOG7P5T07; -.
DR   TreeFam; TF352118; -.
DR   Reactome; REACT_294285; TAK1 activates NFkB by phosphorylation and activation of IKKs complex.
DR   Reactome; REACT_297840; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; REACT_308175; activated TAK1 mediates p38 MAPK activation.
DR   Reactome; REACT_321905; Interleukin-1 signaling.
DR   Reactome; REACT_336915; NOD1/2 Signaling Pathway.
DR   NextBio; 20831757; -.
DR   Proteomes; UP000009136; Chromosome 18.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0008180; C:COP9 signalosome; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IEA:Ensembl.
DR   GO; GO:0043234; C:protein complex; ISS:UniProtKB.
DR   GO; GO:0031982; C:vesicle; ISS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0032500; F:muramyl dipeptide binding; IEA:Ensembl.
DR   GO; GO:0042834; F:peptidoglycan binding; IEA:Ensembl.
DR   GO; GO:0071225; P:cellular response to muramyl dipeptide; ISS:UniProtKB.
DR   GO; GO:0071224; P:cellular response to peptidoglycan; IEA:Ensembl.
DR   GO; GO:0002367; P:cytokine production involved in immune response; IEA:Ensembl.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0016045; P:detection of bacterium; IEA:Ensembl.
DR   GO; GO:0032498; P:detection of muramyl dipeptide; IEA:Ensembl.
DR   GO; GO:0002381; P:immunoglobulin production involved in immunoglobulin mediated immune response; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; ISS:UniProtKB.
DR   GO; GO:0002227; P:innate immune response in mucosa; IEA:Ensembl.
DR   GO; GO:0071608; P:macrophage inflammatory protein-1 alpha production; IEA:Ensembl.
DR   GO; GO:0030277; P:maintenance of gastrointestinal epithelium; IEA:Ensembl.
DR   GO; GO:0044130; P:negative regulation of growth of symbiont in host; IEA:Ensembl.
DR   GO; GO:0002862; P:negative regulation of inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0032701; P:negative regulation of interleukin-18 production; IEA:Ensembl.
DR   GO; GO:0032703; P:negative regulation of interleukin-2 production; IEA:Ensembl.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR   GO; GO:0002710; P:negative regulation of T cell mediated immunity; IEA:Ensembl.
DR   GO; GO:0034136; P:negative regulation of toll-like receptor 2 signaling pathway; IEA:Ensembl.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0070431; P:nucleotide-binding oligomerization domain containing 2 signaling pathway; ISS:UniProtKB.
DR   GO; GO:0050871; P:positive regulation of B cell activation; IEA:Ensembl.
DR   GO; GO:0006965; P:positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteria; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0046645; P:positive regulation of gamma-delta T cell activation; IMP:BHF-UCL.
DR   GO; GO:0002925; P:positive regulation of humoral immune response mediated by circulating immunoglobulin; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0050718; P:positive regulation of interleukin-1 beta secretion; IEA:Ensembl.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; IEA:Ensembl.
DR   GO; GO:0032740; P:positive regulation of interleukin-17 production; IEA:Ensembl.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IEA:Ensembl.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0002830; P:positive regulation of type 2 immune response; ISS:BHF-UCL.
DR   GO; GO:0042981; P:regulation of apoptotic process; IEA:InterPro.
DR   GO; GO:0090022; P:regulation of neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0032495; P:response to muramyl dipeptide; IDA:BHF-UCL.
DR   Gene3D; 1.10.533.10; -; 2.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR011029; DEATH-like_dom.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR007111; NACHT_NTPase.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   Pfam; PF00619; CARD; 2.
DR   SUPFAM; SSF47986; SSF47986; 2.
DR   SUPFAM; SSF52540; SSF52540; 1.
DR   PROSITE; PS50209; CARD; 2.
DR   PROSITE; PS51450; LRR; 5.
DR   PROSITE; PS50837; NACHT; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cell membrane; Complete proteome; Cytoplasm; Immunity;
KW   Innate immunity; Leucine-rich repeat; Membrane; Nucleotide-binding;
KW   Polymorphism; Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN         1   1013       Nucleotide-binding oligomerization
FT                                domain-containing protein 2.
FT                                /FTId=PRO_0000375804.
FT   DOMAIN        1     95       CARD 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN       99    191       CARD 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00046}.
FT   DOMAIN      266    591       NACHT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00136}.
FT   REPEAT      764    785       LRR 1.
FT   REPEAT      789    809       LRR 2.
FT   REPEAT      817    838       LRR 3.
FT   REPEAT      845    866       LRR 4.
FT   REPEAT      873    893       LRR 5.
FT   REPEAT      901    922       LRR 6.
FT   REPEAT      929    949       LRR 7.
FT   REPEAT      957    978       LRR 8.
FT   REPEAT      985   1008       LRR 9.
FT   NP_BIND     272    279       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00136}.
FT   REGION      214    247       Required for CARD9 binding.
FT                                {ECO:0000250|UniProtKB:Q9HC29}.
FT   MOTIF        36     50       ATG16L1-binding motif.
FT   VARIANT      70     70       T -> A. {ECO:0000269|PubMed:16897345}.
FT   VARIANT     196    196       V -> M. {ECO:0000269|PubMed:16897345}.
FT   VARIANT     505    505       T -> N. {ECO:0000269|PubMed:16897345}.
FT   VARIANT     681    681       R -> Q. {ECO:0000269|PubMed:16897345}.
FT   VARIANT     689    689       R -> H. {ECO:0000269|PubMed:16897345}.
FT   VARIANT     733    733       C -> R. {ECO:0000269|PubMed:16897345}.
FT   VARIANT    1007   1007       Q -> L. {ECO:0000269|PubMed:16897345}.
**
**   #################    INTERNAL SECTION    ##################
**EV ECO:0000250; -; XXX; 01-JAN-1900.
**EV ECO:0000250; UniProtKB:Q9HC29; BAP; 19-FEB-2015.
**EV ECO:0000255; PROSITE-ProRule:PRU00046; XXX; 01-JAN-1900.
**EV ECO:0000255; PROSITE-ProRule:PRU00136; XXX; 01-JAN-1900.
**EV ECO:0000269; PubMed:16897345; XXX; 01-JAN-1900.
**EV ECO:0000305; -; XXX; 01-JAN-1900.
**ZA AMB, 27-APR-2009;
**ZB SYP, 21-FEB-2013; SYP, 21-AUG-2013; ANS, 25-NOV-2013; SYP, 06-MAR-2014;
**ZB BAP, 27-FEB-2015;
SQ   SEQUENCE   1013 AA;  112800 MW;  ACAE5F8C4BEFE11B CRC64;
     MCAQDAFQTQ RSQLVELLVS GSLEGFESIL DRLLSREVLS WEDYEGLSLV GQPISHLARR
     LLDTIWNKGT WGCEQLTAAV REAQADSQPP ELPSSWDPHS PHPARDLQSH RPAIVRRLYG
     HVEGVLDLTQ QRGFISQYET DEIRRPIFTS SQRARRLLDL ATVKANGLAA FLLQCIQELP
     VPLALPFEDA ACKKYVSKLR TVISAQSRFL STYDGAENLC LEEVYTENVL EIQMEVGMAG
     PSQQSPTTLG LEELFSTRDH FNKEADTVLV VGEAGSGKST LLQQLHLLWA SGRAFQEFLF
     VFPFSCRQLQ CLVKPLSMRT LLFEHCCWPD LGPQDVFQVL LDHPERILLT FDGFDEFRFR
     FTDQERHCCP TAPTSVQSLL FNLLQGNLLK NARKVLTSRP SAVSASLRKH VRTELSLKGF
     SEEGIELYLR KRHREPGVAD RLLCLLRATS ALHGLCHLPV FSWMVSKCHE ELLLQGRGSP
     KTTTDMYLLI LRHFLLHASP LPLATHGLGP SLIQGRLPTL LHLGRLALWG LGTCCYVFSA
     KQLQAAHVDS EDLSLGFLVL AKRVVPGSTA PLEFLHITFQ CFFAAFYLAL SADTPPSSLR
     HLFQDHRPES SPLARVLPKL FLRGSRCREG SVAALLQGAE PHNLQITGAF LAGLLSQEHR
     SLLAECQASE TALLRRWDCV RRCLTRSLRE HFRSIPPALP GEAKSMHALP GFLWLIRSLY
     EMQEERLARE AVCRLNVGHL KLTFCGVGPA ECAALAFVLR HLRRPVALQL DHNSVGDIGV
     EQLLPCLGVC KALYLRDNNI SDRGICKLVE HALRCEQLQK LALFNNKLTD GCAHSMARLL
     ACKQNFLALR LGNNHITAAG AEVLAQGLRT NNSLQFLGFW GNQVGDEGAQ ALAAALGDHQ
     SLRWLSLVGN NIGSVGAQAL ALMLEKNMAL EELCLEENHV QDEGVCFLAK GLARNSSLKV
     LKLSNNHISS LGAEALLRAL EKNDTILEVW LRGNTFSPEE IEKLSHQDTR LLL
//